Sahin Gül received a bachelor’s degree in Biochemistry from the Ege University (Turkey) in 2007 and received a master’s degree in biochemistry and biotechnology from Ghent University. He earned a PhD in biochemistry and biotechnology from the University of Ghent and Flanders Institute for Biotechnology in 2016. Dr. Gül presently works as research scientist at Caelus Health and leading a R&D team located at the Jlinx incubator at the campus of Janssen Pharmaceutica in Beerse. He is coordinating an international R&D project focusing on the development of novel microbiota based therapeutic product for the prevention or early treatment of type two diabetes and metabolic syndrome.
MEET SAHIN GÜL AT #KFG2018
Sahin Gül will give a presentation in the session "Future Platforms to DISCOVER":
'Microbiome Therapeutics for the reduction of insulin resistance and prevention of Type 2 Diabetes'
Obesity is associated with several conditions, the most serious of which is type 2 diabetes (T2DM). T2DM is a metabolic disease that is characterized by hyperglycemia as a result of impaired sensitivity to insulin. At the year 2015 over 415 million individuals were estimated to have diabetes, and this is expected to increase to over 642 million by 2040. T2DM is the seventh leading cause of death and can lead to serious health complications, including heart attack, stroke, blindness and kidney failure. In 2015, an estimated 1.6 million deaths were directly caused by diabetes. Early diagnosis and intervention is the starting point for the prevention of T2DM.
There is a strong need for safe, affordable and effective solutions to prevent the development of T2DM, particularly in high-risk individuals. Caelus Health is a biotech company based in Amsterdam and Beerse, which is developing an entirely new class of Microbiome Therapeutics for the reduction of insulin resistance and prevention of Type 2 Diabetes (T2DM) in people with metabolic syndrome. We are developing novel microbiota based medicinal products based on living commensal microorganisms to benefit health and treat cardio-metabolic diseases such as T2DM and liver disorders (NAFLD/NASH). As such bacterial species naturally occur in humans, MMP based on intestinal microorganisms have an excellent safety profile for oral applications in human and hold a major promise for intervention.